

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)



(10) International Publication Number
WO 2021/163066 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/US2021/017276

(22) International Filing Date:
09 February 2021 (09.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/972,519 10 February 2020 (10.02.2020) US
63/055,627 23 July 2020 (23.07.2020) US
63/140,714 22 January 2021 (22.01.2021) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventor; and

(71) Applicant: MCININCH, James D. [US/US]; 675 West
Kendall Street, Henri A. Termeer Square, Cambridge, MA
02142 (US).

(72) Inventors: KEATING, Mark; 675 West Kendall Street,
Henri A. Termeer Square, Cambridge, MA 02142 (US).
SCHLEGEL, Mark K.; 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, MA 02142 (US). CAS-
TORENO, Adam; 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, MA 02142 (US). JADHAV, Vas-
ant R.; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). KAITTANIS, Charalam-
bos; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US). CASTELLANOS-RIZAL-
DOS, Elena; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US). PANDYA, Bhaumik
A.; 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, MA 02142 (US).

(74) Agent: KOYFMAN, Hannah, R. et al.; Lando & Anastasi,
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/163066 A1

(54) Title: COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION

(57) Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.